Altered gene regulation is more widespread in cancer than expected

July 10, 2018, Baylor College of Medicine
Credit: CC0 Public Domain

A large-scale study provides new insights into the mechanisms that can lead to cancer. It can happen when genes mutate, but cancer also can occur when the genetic regions involved in regulating gene expression change. In this study, the researchers used whole genome sequencing data to analyze all the genes of 1,448 cancers of 18 different types looking to identify genes whose expression was altered, not by mutation but as a result of changes in the genetic regions that regulate them. The study appears in the journal Cell Reports.

"The includes genes—sequences of DNA that encode the proteins that keep our body working—and regulatory regions adjacent to genes, which are sequences of DNA that regulate gene expression," said corresponding author Dr. Chad Creighton, associate professor of medicine and member of the Dan L Duncan Comprehensive Cancer Center division of biostatistics at Baylor College of Medicine. "In the old days, scientists thought about the regulatory regions as representing 'junk' DNA because they do not make proteins, but in fact they play a critical role. There is an intricate network of regulatory molecules that affect which genes are expressed."

Cancer may develop because of mutations that happen within a protein-coding gene and, as a result, knock out or modify that protein's function. Cancer also may happen because of structural rearrangements, which are pieces of DNA that jump from one part of the genome to another causing rearrangement of many genes.

"We found that structural rearrangements can occur within protein-coding genes and alter the protein's function," Creighton said. "Rearrangements also can occur within the regulatory regions, and although they do not affect the protein-coding genes themselves, they can dramatically alter their expression. For instance, structural rearrangements can turn off , such as p53 and PTEN, or turn on oncogenes such as TERT, which promotes cancer growth."

In this study, working with the Cancer Genome Atlas, a publicly available data set that allows researchers to look at what many types of cancers have in common, Creighton and his colleagues analyzed a large collection of patient cases—1,448 cancers of 18 different types—looking to identify more genes whose expression was altered as a result of structural rearrangements within the regulating .

Creighton and his colleagues found that a number of cancers without alterations within specific genes do involve structural rearrangements that can be affecting the expression of those same genes. They identified hundreds of genes for which structural rearrangements in their regulatory regions were associated with altered expression in cancer.

"We knew of individual genes that are deregulated by structural of , but it was surprising to see this as a more widespread phenomenon than we had expected," Creighton said. "I don't think this has been looked at as deeply before, so this adds to the current body of knowledge. Our next step is to conduct whole genome sequencing at a higher resolution to find even more -associated that are affected by this mechanism."

Explore further: New breast cancer targets

More information: Cell Reports (2018). DOI: 10.1016/j.celrep.2018.06.025

Related Stories

New breast cancer targets

May 4, 2018
Genome-wide association studies (GWAS) have identified more than 150 genetic variations associated with increased risk for breast cancer. Most of these variants are not located in protein-coding gene regions but are assumed ...

Even DNA that doesn't encode genes can drive cancer

April 2, 2018
Most of the human genome—98 percent—is made up of DNA but doesn't actually encode genes, the recipes cells use to build proteins. The vast majority of genetic mutations associated with cancer occur in these non-coding ...

Novel classification can lead to new ways to diagnose and treat cancer

February 12, 2018
A novel approach to studying cancer has enabled researchers to group about 10,000 human cancers of 32 different types into 10 classes based on the molecular pathways that drive tumor growth. A better understanding of these ...

Unraveling role of tumor suppressor in gene expression and ovarian tumorigenesis

June 26, 2018
The tumor suppressor protein ARID1A controls global transcription in ovarian epithelial cells, according to new research conducted at The Wistar Institute, which provided mechanistic insight into tumorigenesis mediated by ...

New regions of genetic material are involved in the development of colon cancer

July 23, 2014
Most research on human cancer genes have been focused on the regions of the coding genome (exons) that are to be translated in the form of amino acids thus proteins. But just before each gene, there is a regulatory region ...

Researchers pinpoint key regulatory role of noncoding genes in prostate cancer development

August 15, 2016
Prostate cancer researchers studying genetic variations have pinpointed 45 genes associated with disease development and progression.

Recommended for you

New drug candidate makes cancer cells more sensitive to radiotherapy

September 26, 2018
Researchers from Karolinska Institutet and Kancera AB have developed a molecule that makes cancer cells sensitive to radiotherapy. In a study published in Nature Communications, the researchers describe a new way to block ...

Aspirin could play valuable role as additional treatment for cancer

September 26, 2018
Regular use of aspirin could help in the treatment of some cancers, finds a new review of 71 medical studies.

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.